Payment overview · 2025
General Payments
$91.43
5 reported records · 4 companies
Healthcare provider profile · identity verified
Kyle Anthony Aldinger, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHELBY, NC · NPI 1043203441
Verified facts
What the public records show
CMS Open Payments records show Kyle Anthony Aldinger, MD received $91.43 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.31 | 36.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.95 | 27.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.72 | 18.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.45 | 18.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.43 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.31 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 211 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
211 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 655 | 179 |
| Omeprazole | Omeprazole | 580 | 156 |
| Gabapentin | Gabapentin | 494 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 467 | 127 |
| Lisinopril | Lisinopril | 460 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 125 |
| Hydrochlorothiazide | Hydrochlorothiazide | 427 | 122 |
| Metformin Hcl | Metformin Hcl | 331 | 88 |
| Losartan Potassium | Losartan Potassium | 316 | 89 |
| Diclofenac Sodium | Diclofenac Sodium | 280 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 237 | 63 |
| Celecoxib | Celecoxib | 213 | 53 |
| Eliquis | Apixaban | 211 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 197 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 55 |
| Simvastatin | Simvastatin | 182 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 49 |
| Montelukast Sodium | Montelukast Sodium | 178 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 56 |
| Clonazepam | Clonazepam | 153 | 42 |
| Tramadol Hcl | Tramadol Hcl | 151 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 47 |
| Furosemide | Furosemide | 148 | 49 |
| Glipizide | Glipizide | 140 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 42 |
| Trazodone Hcl | Trazodone Hcl | 134 | 35 |
| Propranolol Hcl | Propranolol Hcl | 131 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 30 |
| Carvedilol | Carvedilol | 125 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 33 |
| Sertraline Hcl | Sertraline Hcl | 121 | 31 |
| Lorazepam | Lorazepam | 111 | 29 |
| Potassium Chloride | Potassium Chloride | 111 | 30 |
| Meloxicam | Meloxicam | 110 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 37 |
| Famotidine | Famotidine | 100 | 25 |
| Baclofen | Baclofen | 98 | 32 |
| Prednisone | Prednisone | 93 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 27 |
| Mirtazapine | Mirtazapine | 91 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 23 |
| Allopurinol | Allopurinol | 85 | 24 |
| Farxiga | Dapagliflozin Propanediol | 79 | 18 |
| Atenolol | Atenolol | 77 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 22 |
| Finasteride | Finasteride | 73 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 58 |
| Synthroid | Levothyroxine Sodium | 66 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 15 |
| Pregabalin | Pregabalin | 54 | 20 |
| Terazosin Hcl | Terazosin Hcl | 54 | 13 |
| Metformin Hcl Er | Metformin Hcl | 52 | 16 |
| Spironolactone | Spironolactone | 52 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Lovastatin | Lovastatin | 45 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 30 |
| Diazepam | Diazepam | 42 | suppressed |
| Ozempic | Semaglutide | 42 | 12 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | 12 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | 12 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 15 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 27 |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Fluconazole | Fluconazole | 21 | 14 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 13 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.43 · 5 records | Novo Nordisk Inc | AREXVY, ELIQUIS, NURTEC ODT, QULIPTA, SHINGRIX, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error